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ABSTRACT 
Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course. Microarray studies allowed 
highlight genes differentially expressed in this pathology. In this study, we have evaluated the prognostic significance 
of SEPT10 expression in CLL patients. Results were correlated with immunoglobulin heavy-chain variable (IGHV) 
genes mutational status, genomic rearrangements and clinical parameters. SEPT10 mRNA levels were determined by 
quantitative real-time PCR in 70 newly diagnosed CLL patients consecutively referred to our Institution. A wide het- 
erogeneity for SEPT10 expression was found. Gene upregulation was observed in 18.5% of cases. The univariate analy- 
sis showed a positive association between gen expression and platelet count (p < 0.0001) and a negative correlation with 
hemoglobin levels (p = 0.0094). Although no significant differences were observed, mean treatment free survival was 
shorter in patients with high expression (31 months) with respect to those with low mRNA levels (72 months). Cases 
with abnormal karyotypes had increased expression compared to those with normal karyotypes and no association be- 
tween gene expression and FISH (fluorescence in situ hybridization) risk groups and IGHV mutational status was found. 
Cases using IGHV3-23 gene rearrangement had low SEPT10 expression. Our results showed an association between 
SEPT10 expression and features of adverse outcome but without independent prognostic value. The study of SEPT10 
expression may be important for a better understanding of disease heterogeneity, adding further information to those 
provided by established prognostic factors. 
 
Keywords: Chronic Lymphocytic Leukemia; SEPT10 Expression; FISH; Cytogenetics; IGHV Mutational Status 
1. Introduction 
Chronic lymphocytic leukemia (CLL) is the most fre- 
quent type of adult leukemia in Western world. The dis- 
ease is characterized by a highly variable clinical course, 
with time to progression ranging from months to decades 
[1]. Clinical staging systems have been very useful in 
guiding disease management and treatment decisions. 
However, these staging systems have shown a limited 
capacity to predict clinical outcome at an early stage of 
the disease. Based on this situation, a variety of bio- 
markers have been investigated as potential prognostic 
factors in CLL. They include genomic aberrations, muta- 
tional status of immunoglobulin heavy-chain variable 
(IGHV) genes and expression profiles of different genes. 
Particularly, fluorescence in situ hybridization (FISH) 
analysis allowed the identification of distinct cytogenetic  
risk groups, in which patients with deletion 13q14 as a 
single alteration have a better outcome, while patients 
with deletions 11q22 or 17p13 show the shortest median 
survival and, cases with trisomy 12 have an intermediate 
prognosis [2]. In addition, IGHV defines two disease 
subgroups: one expressing mutated (M) IGHV segments 
with a more favorable clinical course, and the other ex- 
pressing unmutated (UM) IGHV segments, associated to 
a poor outcome [3,4]. 
More recently, microarray studies allowed the estab- 
lishment of a gene expression profile characteristic of 
CLL which highlights differentially expressed genes in 
patients with stable or progressive disease. Among them, 
SEPT10 (septin 10), located at 2q13 band, has been pro- 
posed as a probable prognostic marker in CLL. This gene 
belongs to septins family, an evolutionarily conserved 
group of at least 14 distinct genes encoding GTP (gua-  
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nosine triphosphate)-binding proteins and filament-for- 
ming proteins, involved in multiple cellular processes 
like vesicle trafficking, apoptosis, remodeling of the cy- 
toskeleton, infection, neurodegeneration and neoplasia 
[5]. Many evidences have indicated that some septins 
were abnormally expressed in certain kinds of tumors 
and the altered expressions were related to the process of 
carcinogenesis [6]. In addition, mammalian septins mo- 
dulate microtubule dynamics through the interaction with 
a microtubule associated protein, MAP4 [7], and par-
ticularly SEPT10 is an important regulator of micro-tu- 
bule stability [8]. In CLL, the literature showed that 
SEPT10 mRNA expression correlates with both high 
lipoprotein lipase (LPL) expression and UM IGHV gene 
status [9,10]. However, its association with other charac- 
teristics of the disease has been scarcely explored. In this 
study we have evaluated the prognostic significance of 
SEPT10 expression in CLL patients in relation to IGHV 
mutational status, genomic rearrangements and clinical 
parameters. 
2. Material and Methods 
2.1. Patients  
Our cohort included 70 newly diagnosed CLL patients 
(43 males; median age: 65 years, range: 38 - 83 years) 
consecutively referred to our Institution. Patients were 
diagnosed according to the International Workshop on 
Chronic Lymphocytic Leukemia criteria [11]. Stage was 
assessed according to the Rai classification [12]. Clinical 
stages showed the following distribution: 0: 25 patients 
(36%), I: 10 (14%), II: 22 (31%), III: 7 (10%) and, IV: 6 
(9%). All individuals provided their informed consent. 
The study was approved by the local Ethics Committee. 
2.2. Cytogenetic and FISH Analysis 
Chromosome analysis was performed on peripheral blood 
lymphocytes, cultured for 96 hours at 37˚C in F-12 me- 
dium supplemented with 15% of fetal calf serum, stimu- 
lated with Pokeweed mitogen and Lipopolysaccharide, or 
in presence of the immunostimulatory CpG-oligonu- 
cleotide (2 μM) and interleukin 2 (200 U/ml) for 72 hs. 
Slides were prepared by conventional method. G-banding 
technique was used. 
For FISH analysis, slides were hybridized with LSI 
TP53/ATM/13q14/13q34/CEP12 DNA probes (Vysis- 
Abbott), according to manufacturer’s protocol. Two hun- 
dred interphase nuclei were analyzed for each probe. The 
cut-off for positive values (mean of normal control + 3 
standard deviations), determined from samples of ten 
cytogenetically normal donors, were: 3.02%, 10.2%, 
7.7% and 5.1% for trisomy 12, monosomies of D13S319 
(13q14), ATM (11q22) and TP53 (17p13), respectively.  
2.3. mRNA Extraction and SEPT10  
Expression Analysis 
Total RNA was extracted with Trizol reagent (Invitrogen, 
Buenos Aires, Argentina) from mononuclear cells iso- 
lated on a Ficoll-Paque Plus (GE Healthcare Bio-Sci- 
ences, Uppsala, Sweden) density gradient from periph- 
eral blood samples of patients and healthy controls. The 
cDNA synthesis was carried out using Moloney Murine 
Leukemia Virus Reverse Transcriptase and random 
primer (Promega, Madison, WI, USA). SEPT10 mRNA 
levels were determined by quantitative real-time PCR 
(qRT-PCR) in a LightCycler 2.0 system (Roche Diag- 
nostics, Mannheim, Germany), based on SYBR Green I 
methodology, and utilizing the Lightcycler software. 
Briefly, 1 μg of total RNA was amplified in the presence 
of 0.5 μM of specific primers for SEPT10 [10] or the 
housekeeping gene GAPDH (Glyceraldehyde 3-phos- 
phate dehydrogenase) [13] with the following protocol: 
10 min at 95˚C for initial denaturation, 50 cycles of 15 s 
at 95˚C, 10 s at 62˚C and 15 s at 72˚C, followed by the 
respective melting curve. All measurements included a 
determination of the standards and the use of a no-tem- 
plate as a negative control. 
2.4. IGHV Mutational Status 
The IGHV gene sequences were determined as previ- 
ously described [14]. Briefly, amplification of IGHV re- 
gions by PCR was performed on cDNA using VH 
framework region 1 consensus family specific primers 
(VH1-VH6) and JH primers [15]. When amplifications 
of these primers were unsuccessful, an alternative set of 
primers that anneal to sequences in the leader region 
(LH1-LH6) and one antisense Cµ-primer [16] were used. 
Thermal cycling conditions were 3 min at 93˚C, followed 
by 33 cycles at 94˚C for 30 s, 62˚C for 30 s, 72˚C for 30 
s, elongation at 72˚C for 7 min, and a final step at 4˚C for 
10 min. PCR products were purified in 1% agarose gels, 
sequenced bi-directionally and analyzed on an automated 
DNA sequence analyzer (377 ABI Prism, PE Biosystem, 
Foster City, CA). Sequence data were analyzed using 
IgBLAST (http://www.ncbi.nlm.nih.gov/igblast) and the 
ImMunoGeneTics database (IMGT; http://imgt.cines.fr). 
IGHV sequences with less than 98% homology with re- 
spect to the germline counterpart were considered as M 
while those with homology of 98% or higher were classi- 
fied as UM [3,4]. 
2.5. Statistical Analysis 
Statistical evaluation of mRNA expression data was 
performed using the Mann-Whitney test. Correlations 
between gene expression and clinical variables were 
assessed by using the Kendall’s coefficient. The cut-off 
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point for SEPT10 expression was selected according to 
receiver operating characteristic (ROC) analysis. Group 
wise comparison of the distribution of clinical and 
laboratory variables was performed with the Student t 
test (for quantitative variables) and the χ2 or Fisher’s 
exact test (for categorical variables). Overall survival and 
treatment free survival (TFS) were estimated by the 
Kaplan-Meier method and compared with the log-rank 
test. 
3. Results 
Analysis of data showed a wide heterogeneity for SEPT10 
expression in CLL patients, with cases that overex- 
pressed this gene and others with low levels of transcripts 
(Figure 1). For a better analysis, patients were divided 
into two groups: high expression (SEPT10high) and low 
expression (SEPT10low), according to the cut-off value 
(221.05) obtained by ROC curves. It was quite similar to 
the baseline value of SEPT10 expression observed in 
control samples with our approach (220.3 ± 107.5). 
Upregulation of SEPT10 was found in 13 cases (18.5%) 
(mean ± SE: 720.9 ± 190.5) while the remaining patients 
showed low levels of mRNA transcript (mean ± SE: 
44.26 ± 6.99).  
Furthermore, we would like to determine if SEPT10 
expression profile had clinical significance. The analysis 
according to established prognostic factors in CLL did 
not show differences between patients with high and low 
gene expression, with the exception of age, that was re- 
duced in SEPT10low patients compared to those with high 
mRNA levels (p = 0.006) (Table 1). The univariate 
analysis showed a positive association between gen ex- 
pression and platelet count (p < 0.0001) and a negative 
correlation with hemoglobin levels (p = 0.0094). In ref- 
erence to outcome, although no significant differences 
were observed, mean TFS was shorter in SEPT10high pa- 
tients (31 months) with respect to those with low gene 
expression (72 months). 
We also analyzed SEPT10 expression in relation to 
cytogenetic alterations, FISH risk groups and IGHV mu-  
 
 
Figure 1. Scatter plot showing the wide distribution of 
SEPT10 mRNA levels in chronic lymphocytic leukemia 
(CLL) patients.  
tational status, and a similar distribution of patients in the 
different categories was observed (Table 2). However, 
when SEPT10 mRNA levels were evaluated, patients 
with abnormal karyotypes had increased expression com- 
pared to those with normal karyotypes (Figure 2) and no 
association between gene expression and FISH risk 
groups and IGHV mutational status were found. Ex- 
pression levels were also evaluated in different IGHV 
families and a similar distribution among VH1, VH3 and 
VH4 was observed. More detailed analysis of IGHV 
segments usage showed that IGHV3-23 gene rearrange- 
ment was the most represented in our cohort (7 cases); 
six of them (85.7%) showing low SEPT10 expression, as 
well as the only one case of our series using IGHV3-21 
segment. 
4. Discussion 
CLL is characterized by a heterogeneous clinical course, 
with some patients experiencing rapid disease progres- 
sion and others living for decades without requiring 
treatment. However, classical prognostic parameters have 
a limited capacity to predict clinical outcome at an early 
stage of the disease. In recent years, numerous genetic 
approaches have provided new markers for prognosis and 
response prediction [17]. Among them, a considerable 
number of genes differentially expressed in CLL were 
identified, including SEPT10 [18,19], which role as 
prognostic factor in this pathology was scarcely evalu- 
ated [9,10]. In this study, we have analyzed SEPT10 
mRNA expression in a cohort of newly diagnosed CLL 
patients. Our series showed a low percentage of patients 
with SEPT10 overexpression (18% of cases), value close 
to the 27% observed by Van’t Veer et al. [10], indicating 
that deregulation of this gene is limited to a specific sub- 
group of patients. Besides, expression analysis showed a 
wide heterogeneity of mRNA levels, which could be re- 
lated to variations in expression control at the transcript- 
tional, post-transcriptional and translational levels or  
 
 
Figure 2. SEPT10 mRNA expression profile in chronic lym- 
phocytic leukemia patients with normal (N) and abnormal 
(A) karyotypes. 
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Table 1. SEPT10 gene expression according to the known prognostic factors in CLL. 
Sex (%) RAI stages (%) Expression 
groups 
(No. cases) 
Mean 
age 
(years) M F 0 I - II III - IV
Mean % 
lymphocytes 
(range) 
Mean platelet 
count (×109/L) 
(range) 
Mean Hb 
(g/dL) (range) 
Mean LDH 
(UI/L) (range) 
Mean β2M 
(g/ml) 
(range) 
SEPT10low  
< 221.5 (57)  61.7 65 35 31.8 47.7 20.5 75.5 (49 - 98) 192.5 (33 - 378) 12.9 (7.4 - 15.5) 383 (120 - 680) 2.6 (1.1 - 3.6)
SEPT10high  
≥ 221.5 (13) 71.4
a 50 50 54.5 36.4 9.1 66.2 (54 - 87) 273.1 (76 - 900) 12.2 (5.6 - 15.8) 418 (269 - 497) 2.5 (1.2 - 3.6)
M: male; F: female; Hb: hemoglobine; LDH: lactate dehidrogenase; 2M: beta 2 microglobuline. aSignificant differences respect to SEPT10low patients: p = 
0.006. 
 
Table 2. SEPT10 gene expression according to cytogenetic, FISH and IGHV groups. 
Cytogenetics (%) FISH (%) IGHV (%) Expression groups 
(No. of cases) NK AK NF AF M UM 
SEPT10low < 221.5 (57) 72.5 27.5 71.5 28.5 55.6 44.4 
SEPT10high ≥ 221.5 (13) 66.7 33.3 77.7 22.3 75.0 25.0 
NK: normal karyotype; AK: abnormal karyotype; NF: normal FISH; AF: abnormal FISH; IGHV: immunoglobulin heavy-chain variable gene; M: mutated; UM: 
unmutated. 
 
associated to the presence of alternative splice variants 
[5]. Citoquines or mitogens that induce proliferation and 
differentiation through different signaling pathways may 
also influence the activity of this gene. 
As previously referred, clinical significance of SEPT10 
mRNA expression was scarcely evaluated in the litera- 
ture [9,10,20]. In this aspect, our results add new infor- 
mation about it. Thus, we found association between 
SEPT10 expression and age, platelet count and hemoglo- 
bin levels. In addition, although no significant differ-
ences were found, longer TFS was observed in our 
SEPT10low subgroup, supporting a previous report show- 
ing that patients with high SEPT10 expression required 
earlier treatment [9]. Simultaneously, we have evaluated 
for the first time the association between cytogenetic 
alterations and SEPT10 expression and cases with ab- 
normal karyotypes had a non-significant SEPT10 upregu- 
lation compared to those with normal karyotypes. These 
findings are of interest taking into account the adverse 
clinical impact of structural abnormalities and complex 
karyotypes in CLL [21-23], suggesting a relationship 
between SEPT10 expression and accumulation of chro- 
mosome alterations in leukemic cells. In addition, we did 
not observe correlations between SEPT10 levels and 
FISH risk groups, coincident with the sole report in the 
literature that analyzed this aspect [10].  
Unlike to those observed in the literature [9,10,20], we 
did not find association between SEPT10 expression and 
IGHV mutational status. A study in a larger series may be 
necessary to clarify this point. In reference to IGHV 
segment usage, association between low SEPT10 mRNA 
levels and IGHV4-34 and high expression with IGHV1- 
69 gene rearrangement, were reported [10]. Although the 
number of our cases is not large, an association between 
IGHV3-23 and low expression was observed. Interest- 
ingly, different authors [10,24] have detected lower 
SEPT10 expression in IGHV3-21 expressing CLL, sug- 
gesting the inability of SEPT10 expression to recognize 
the poor prognosis of this CLL subset. The only one case 
of our series expressing IGHV3-21 segment supports 
these findings. 
In conclusion, our results showed a wide heterogeneity 
in the expression profile of SEPT10 with overexpression 
in a subgroup of CLL patients. The correlation with 
clinical characteristics showed association with features 
of adverse outcome but without independent prognostic 
value. Thus, the study of this gene may be important for 
a better understanding of the disease variability, and 
could be used in combination with other markers, adding 
further information to those provided by established 
prognostic factors. In this line, an association between 
SEPT10 and LPL [9], which overexpression was related 
to adverse clinical outcome in CLL [25], have been pre- 
viously described, suggesting that SEPT10 could direct 
LPL to the cell surface by establishing a link between 
proteoglycans (the cell surface LPL receptor) and the 
actin cytoskeleton [5,9]. The understanding of biological 
mechanism of the disease will contribute to future risk 
stratification strategies with potential value in treatment 
decisions. 
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